Skip to main content
Fig. 7 | BMC Immunology

Fig. 7

From: Subcutaneous immunoglobulin replacement therapy in patients with immunodeficiencies – impact of drug packaging and administration method on patient reported outcomes

Fig. 7

Respondent symptom state and perceived health status in the vial and PFS cohorts, stratified by SCIg administration method (pump and manual push). (A) Proportion of respondents who responded ‘affirmative’ to whether they were at an acceptable symptom state (as measured using PASS), (B) proportion of respondents who described their current health status as ‘fair’, ‘good’, ‘very good’ or ‘excellent’ (as measured using GHP), and (C) transformed scores for PROMIS GPH-2 and GMH-2. The complementary response category for PASS was ‘negative’ and for GHP were ‘poor’ or ‘very poor’. GHP, general health perception; GMH-2, global mental health 2; GPH-2, global physical health 2; IVIg, intravenous immunoglobulin; PASS, patient acceptable symptom state; PFS, pre-filled syringes; PROMIS, patient-reported outcomes measurement information system; SCIg, subcutaneous immunoglobulin

Back to article page